...
首页> 外文期刊>Neuromuscular disorders: NMD >Steroid therapy in an alpha-dystroglycanopathy due to GMPPB gene mutations: A case report
【24h】

Steroid therapy in an alpha-dystroglycanopathy due to GMPPB gene mutations: A case report

机译:由于GMPPB基因突变引起的α-Dystrogycanopathy的类固醇疗法:案例报告

获取原文
获取原文并翻译 | 示例
           

摘要

Alpha-dystroglycanopathies are a group of progressive and untreatable neuromuscular disorders, due to aberrant alpha-dystroglycan glycosylation. We describe the effects of a short-term cycle of corticosteroid therapy in a 9-year-old boy, affected by an alpha-dystroglycanopathy due toGMPPBgene mutations. The patient was affected by a congenital progressive muscular dystrophy since the first month of life, associated with psychomotor delay, seizures, and congenital bilateral cataracts. Despite physical therapy he had a progressive motor impairment. At the age of 9 years, he was treated with 0.75?mg/kg/day of prednisone for 3 months and showed improvements in muscle strength and function scores and creatine kinase reduction. When steroid therapy was discontinued he showed again clinical and biochemical deterioration. These data suggest that corticosteroid may be considered as a treatment for patients with alpha-dystroglycanopathies due toGMPPBmutations.
机译:由于异常的α-当糖苷糖基化,α-亚泛蛋白病是一组渐进和无法治疗的神经肌肉障碍。 我们描述了皮质类固醇治疗的短期循环在一个9岁的男孩中受到α-制霉蛋白突变的影响的影响。 由于生命的第一个月以来,患者受到先天性渐进性肌营养不良的影响,与精神接种,癫痫发作和先天性双侧白内障有关。 尽管物理治疗,但他有一个渐进的电机损伤。 9岁时,他患有0.75毫克/千克/天的泼尼松,持续3个月,并显示出肌肉力量和功能评分的改善和肌酸激酶还原。 当停止类固醇疗法时,他再次表现出临床和生化劣化。 这些数据表明皮质类固醇可以被认为是对由于THMPPMutations的α-蒽基因糖病的患者的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号